Townsville Hospital and Health Service
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
John, Bobby
INORMUS_INTERNATIONAL, NCT02150980: INternational ORthopaedic MUlticenter Study in Fracture Care (INORMUS)

Completed
N/A
39797
RoW
McMaster University, Canadian Institutes of Health Research (CIHR), McMaster Surgical Associates, National Health and Medical Research Council, Australia, Hamilton Health Sciences Corporation
Fractures or Dislocations
11/23
11/23
Foo, Hong
ROADMAP, NCT06771050: Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform () Trial is an International RCT Evaluating the Effect of a Range of Clinical Surgical and Antibiotic Interventions on Treatment Success 12 Mths Post-platform Entry in Adults With Prosthetic Joint Infection (PJI)

Not yet recruiting
4
2500
RoW
Debridement and Implant Retention (DAIR), Revision Arthroplasty - Single stage revision, Antibiotic Choice, No intervention: Standard of Care "Backbone antibiotics", Intervention: Standard of care " Backbone antibiotics" + Rifampicin antibiotics, Antibiotic duration Part A - Single stage revision, shorter duration - 6 weeks, longer duration - 12 weeks, Antibiotic Duration Part B - Two stage revision, Extended antibiotic prophylaxis following 2nd stage Revision operation, No extended antibiotic prophylaxis following 2nd stage Revision operation
University of Newcastle, Australia, Hunter Medical Research Institute (HMRI), The University of Western Australia, Michael Garron Hospital, Aotearoa Clinical Trials, Exeter Orthopaedic Trial unit, University of Sydney, University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections
02/28
12/29
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
ASCOT, NCT04483960: Australasian COVID-19 Trial () ADAptive Platform Trial

Active, not recruiting
3
2200
RoW
(Arm Closed) Nafamostat Mesilate, Nafabelltan, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin, (Arm Closed) Tinzaparin, (Arm Never Opened) Hyperimmune globulin, Nirmatrelvir-Ritonavir, Paxlovid, Remdesivir, Veklury
University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Aotearoa Clinical Trials, Australian and New Zealand Intensive Care Research Centre
SARS-CoV-2 Infection (COVID-19)
07/25
12/25
Farley, Anthony
CLIP II, NCT03991481: The Cryopreserved vs. Liquid Platelets Trial

Active, not recruiting
3
388
RoW
Cryopreserved platelets, Liquid-stored platelets
Australian and New Zealand Intensive Care Research Centre, Australian Red Cross
Surgical Blood Loss, Hemorrhage
07/24
11/25
Taylor, Melanie M
STATIC, NCT03261206 / 2018-001382-17: Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Active, not recruiting
4
334
Europe, Canada, RoW
5-ASA Withdrawal
Alimentiv Inc., Academic Medical Organization of Southwestern Ontario
Crohn Disease, Remission
06/26
06/26
MOST-CIRCUIT, NCT04969887: Combination Immunotherapy in Rare Cancers Under InvesTigation

Active, not recruiting
2
240
RoW
Ipilimumab, YERVOY ®, Nivolumab, Opdivo
Olivia Newton-John Cancer Research Institute, Bristol-Myers Squibb
Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor
03/26
03/28
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
Sabesan, Sabe
MOST-CIRCUIT, NCT04969887: Combination Immunotherapy in Rare Cancers Under InvesTigation

Active, not recruiting
2
240
RoW
Ipilimumab, YERVOY ®, Nivolumab, Opdivo
Olivia Newton-John Cancer Research Institute, Bristol-Myers Squibb
Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor
03/26
03/28

Download Options